Update richtlijn psoriasis 2017

G. E. Van Der Kraaij; Ph I. Spuls; Werkgroep richtlijn psoriasis; D. M.W. Balak; C. I.M. Busard; Y. Chung; O. D. Van Cranenburgh; R. J.B. Driessen; J. J.E. Van Everdingen; F. Van Gaalen; M. De Groot; J. H.F. Hulshuizen; E. M.G.J. De Jong; P. M.J.H. Kemperman; W. J.A. De Kort; I. Laffra; L. L.A. Lecluse; P. P.M. Van Lümig; S. P. Menting; E. P. Prens; J. M.P.A. Van Den Reek; M. M.B. Seyger; H. B. Thio; W. R. Veldkamp; M. Wakkee

Update richtlijn psoriasis 2017

G. E. Van Der Kraaij^*
, Ph I. Spuls
, Werkgroep richtlijn psoriasis
, D. M.W. Balak
, C. I.M. Busard
, Y. Chung
, O. D. Van Cranenburgh
, R. J.B. Driessen
, J. J.E. Van Everdingen
, F. Van Gaalen
, M. De Groot
, J. H.F. Hulshuizen
, E. M.G.J. De Jong
, P. M.J.H. Kemperman
, W. J.A. De Kort
, I. Laffra
, L. L.A. Lecluse
, P. P.M. Van Lümig
, S. P. Menting
, E. P. Prens

J. M.P.A. Van Den Reek, M. M.B. Seyger, H. B. Thio, W. R. Veldkamp, M. Wakkee

^*Corresponding author for this work

Amsterdam UMC

Research output: Contribution to journal › Article › Academic › peer-review

4 Citations (Scopus)

Abstract

The update of the NVDV guideline psoriasis 2017 is summarized. In the update the chapters methotrexate, fumaric acid esters, biologics, children, serum concentrations and antibody formation and quality of life are renewed. In addition chapters on secukinumab, apremilast, choice of treatment, combination treatment, psoriatic arthritis and pregnancy and breastfeeding during biologic treatment have been added. The update is based on the NVDV guideline psoriasis 2011¹, European Dermatology Forum (EDF) guideline Psoriasis 2015² and new search and analyses by the workgroup. The most important differences in the update 2017 compared to the NVDV guideline psoriasis 2011 are discussed.

Original language	English
Pages (from-to)	170-173
Number of pages	4
Journal	Nederlands Tijdschrift voor Dermatologie en Venereologie
Volume	27
Issue number	4
Publication status	Published - 2017

Bibliographical note

Publisher Copyright:
© 2017 De Nederlandse Vereniging voor Dermatologie en Venereologie.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

https://nvdv.nl/storage/app/media/NTvDV%202017-04.pdf

Cite this

Van Der Kraaij, G. E., Spuls, P. I., Werkgroep richtlijn psoriasis, Balak, D. M. W., Busard, C. I. M., Chung, Y., Van Cranenburgh, O. D., Driessen, R. J. B., Van Everdingen, J. J. E., Van Gaalen, F., De Groot, M., Hulshuizen, J. H. F., De Jong, E. M. G. J., Kemperman, P. M. J. H., De Kort, W. J. A., Laffra, I., Lecluse, L. L. A., Van Lümig, P. P. M., Menting, S. P., ... Wakkee, M. (2017). Update richtlijn psoriasis 2017. Nederlands Tijdschrift voor Dermatologie en Venereologie, 27(4), 170-173. https://nvdv.nl/storage/app/media/NTvDV%202017-04.pdf

@article{a8e5d92c7bae4edabed18d7d5bda007f,

title = "Update richtlijn psoriasis 2017",

abstract = "The update of the NVDV guideline psoriasis 2017 is summarized. In the update the chapters methotrexate, fumaric acid esters, biologics, children, serum concentrations and antibody formation and quality of life are renewed. In addition chapters on secukinumab, apremilast, choice of treatment, combination treatment, psoriatic arthritis and pregnancy and breastfeeding during biologic treatment have been added. The update is based on the NVDV guideline psoriasis 20111, European Dermatology Forum (EDF) guideline Psoriasis 20152 and new search and analyses by the workgroup. The most important differences in the update 2017 compared to the NVDV guideline psoriasis 2011 are discussed.",

author = "\{Van Der Kraaij\}, \{G. E.\} and Spuls, \{Ph I.\} and \{Werkgroep richtlijn psoriasis\} and Balak, \{D. M.W.\} and Busard, \{C. I.M.\} and Y. Chung and \{Van Cranenburgh\}, \{O. D.\} and Driessen, \{R. J.B.\} and \{Van Everdingen\}, \{J. J.E.\} and \{Van Gaalen\}, F. and \{De Groot\}, M. and Hulshuizen, \{J. H.F.\} and \{De Jong\}, \{E. M.G.J.\} and Kemperman, \{P. M.J.H.\} and \{De Kort\}, \{W. J.A.\} and I. Laffra and Lecluse, \{L. L.A.\} and \{Van L{\"u}mig\}, \{P. P.M.\} and Menting, \{S. P.\} and Prens, \{E. P.\} and \{Van Den Reek\}, \{J. M.P.A.\} and Seyger, \{M. M.B.\} and Thio, \{H. B.\} and Veldkamp, \{W. R.\} and M. Wakkee",

note = "Publisher Copyright: {\textcopyright} 2017 De Nederlandse Vereniging voor Dermatologie en Venereologie.",

year = "2017",

language = "English",

volume = "27",

pages = "170--173",

journal = "Nederlands Tijdschrift voor Dermatologie en Venereologie",

issn = "0925-8604",

publisher = "Stichting Beheer Tijdschriften Dermatologie",

number = "4",

}

Van Der Kraaij, GE, Spuls, PI, Werkgroep richtlijn psoriasis, Balak, DMW, Busard, CIM, Chung, Y, Van Cranenburgh, OD, Driessen, RJB, Van Everdingen, JJE, Van Gaalen, F, De Groot, M, Hulshuizen, JHF, De Jong, EMGJ, Kemperman, PMJH, De Kort, WJA, Laffra, I, Lecluse, LLA, Van Lümig, PPM, Menting, SP, Prens, EP, Van Den Reek, JMPA, Seyger, MMB, Thio, HB, Veldkamp, WR & Wakkee, M 2017, 'Update richtlijn psoriasis 2017', Nederlands Tijdschrift voor Dermatologie en Venereologie, vol. 27, no. 4, pp. 170-173. <https://nvdv.nl/storage/app/media/NTvDV%202017-04.pdf>

TY - JOUR

T1 - Update richtlijn psoriasis 2017

AU - Van Der Kraaij, G. E.

AU - Spuls, Ph I.

AU - Werkgroep richtlijn psoriasis

AU - Balak, D. M.W.

AU - Busard, C. I.M.

AU - Chung, Y.

AU - Van Cranenburgh, O. D.

AU - Driessen, R. J.B.

AU - Van Everdingen, J. J.E.

AU - Van Gaalen, F.

AU - De Groot, M.

AU - Hulshuizen, J. H.F.

AU - De Jong, E. M.G.J.

AU - Kemperman, P. M.J.H.

AU - De Kort, W. J.A.

AU - Laffra, I.

AU - Lecluse, L. L.A.

AU - Van Lümig, P. P.M.

AU - Menting, S. P.

AU - Prens, E. P.

AU - Van Den Reek, J. M.P.A.

AU - Seyger, M. M.B.

AU - Thio, H. B.

AU - Veldkamp, W. R.

AU - Wakkee, M.

PY - 2017

Y1 - 2017

N2 - The update of the NVDV guideline psoriasis 2017 is summarized. In the update the chapters methotrexate, fumaric acid esters, biologics, children, serum concentrations and antibody formation and quality of life are renewed. In addition chapters on secukinumab, apremilast, choice of treatment, combination treatment, psoriatic arthritis and pregnancy and breastfeeding during biologic treatment have been added. The update is based on the NVDV guideline psoriasis 20111, European Dermatology Forum (EDF) guideline Psoriasis 20152 and new search and analyses by the workgroup. The most important differences in the update 2017 compared to the NVDV guideline psoriasis 2011 are discussed.

AB - The update of the NVDV guideline psoriasis 2017 is summarized. In the update the chapters methotrexate, fumaric acid esters, biologics, children, serum concentrations and antibody formation and quality of life are renewed. In addition chapters on secukinumab, apremilast, choice of treatment, combination treatment, psoriatic arthritis and pregnancy and breastfeeding during biologic treatment have been added. The update is based on the NVDV guideline psoriasis 20111, European Dermatology Forum (EDF) guideline Psoriasis 20152 and new search and analyses by the workgroup. The most important differences in the update 2017 compared to the NVDV guideline psoriasis 2011 are discussed.

UR - https://www.scopus.com/pages/publications/85019837752

M3 - Article

AN - SCOPUS:85019837752

SN - 0925-8604

VL - 27

SP - 170

EP - 173

JO - Nederlands Tijdschrift voor Dermatologie en Venereologie

JF - Nederlands Tijdschrift voor Dermatologie en Venereologie

IS - 4

ER -

Update richtlijn psoriasis 2017

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this